Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells
Kristin E. Brandt,
Kelly C. Falls,
Joshua D. Schoenfeld,
Samuel N. Rodman,
Zhimin Gu,
Fenghuang Zhan,
Joseph J. Cullen,
Brett A. Wagner,
Garry R. Buettner,
Bryan G. Allen,
Daniel J. Berg,
Douglas R. Spitz,
Melissa A. Fath
Affiliations
Kristin E. Brandt
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Kelly C. Falls
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Joshua D. Schoenfeld
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Samuel N. Rodman
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Zhimin Gu
Department of Internal Medicine, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Fenghuang Zhan
Department of Internal Medicine, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Joseph J. Cullen
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States; Department of Surgery, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Brett A. Wagner
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Garry R. Buettner
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Bryan G. Allen
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Daniel J. Berg
Department of Internal Medicine, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States
Douglas R. Spitz
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States; Correspondence to: Free Radical and Radiation Biology Program, B180 Medical Laboratories, Department of Radiation Oncology, Holden Comprehensive Cancer Center, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, United States.
Melissa A. Fath
Free Radical and Radiation Biology Program, Departments of Radiation Oncology, Carver College of Medicine, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, United States; Correspondence to: Free Radical and Radiation Biology Program, B180 Medical Laboratories, Department of Radiation Oncology, Holden Comprehensive Cancer Center, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, United States.
Pharmacological doses (> 1 mM) of ascorbate (a.k.a., vitamin C) have been shown to selectively kill cancer cells through a mechanism that is dependent on the generation of H2O2 at doses that are safely achievable in humans using intravenous administration. The process by which ascorbate oxidizes to form H2O2 is thought to be mediated catalytically by redox active metal ions such as iron (Fe). Because intravenous iron sucrose is often administered to colon cancer patients to help mitigate anemia, the current study assessed the ability of pharmacological ascorbate to kill colon cancer cells in the presence and absence of iron sucrose.In vitro survival assays showed that 10 mM ascorbate exposure (2 h) clonogenically inactivated 40â80% of exponentially growing colon cancer cell lines (HCT116 and HT29). When the H2O2 scavenging enzyme, catalase, was added to the media, or conditionally over-expressed using a doxycycline inducible vector, the toxicity of pharmacological ascorbate was significantly blunted. When colon cancer cells were treated in the presence or absence of 250 µM iron sucrose, then rinsed, and treated with 10 mM ascorbate, the cells demonstrated increased levels of labile iron that resulted in significantly increased clonogenic cell killing, compared to pharmacological ascorbate alone. Interestingly, when colon cancer cells were treated with iron sucrose for 1 h and then 10 mM ascorbate was added to the media in the continued presence of iron sucrose, there was no enhancement of toxicity despite similar increases in intracellular labile iron. The combination of iron chelators, deferoxamine and diethylenetriaminepentaacetic acid, significantly inhibited the toxicity of either ascorbate alone or ascorbate following iron sucrose. These observations support the hypothesis that increasing intracellular labile iron pools, using iron sucrose, can be used to increase the toxicity of pharmacological ascorbate in human colon cancer cells by a mechanism involving increased generation of H2O2. Keywords: Oxidative stress, Redox active iron, Iron sucrose, Catalase, Deferoxamine, Chelators